RxDoctor Payments Data

Karen Fisher

Adult Health · Abington, MANPI 1487610606

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,072 of the $5,081 with a category attached, or 80.2%. 12 manufacturers reported payments, led by Livanova USA, Inc. at 26.1% of the total. Reporting peaked in 2023 at $1,723 and has fallen 66.6% since, to $576 in 2025. Among adult health clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,081in general payments, 2019–2025

Across 216 payments — averaging $23.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$1K
  • AbbVie$767
  • Biohaven Pharmaceuticals, Inc.$689
  • Pfizer$639
  • Lilly USA, LLC$636
  • Biohaven Pharmaceutical Holding Company Ltd.$302
  • plus $723 from 6 others

What the payments were for

  • Travel & lodging$91518%
  • Food & beverage$4,07280%
  • Education$932%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,081 in reported general payments places this provider in the 95th percentile of 671 adult health providers in Massachusetts.

See all adult health providers in Massachusetts

Medicare billing

Part B allowed, 2024
$79,466
Medicare patients
392
Services billed
749

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate16$131,006
Nurtec OdtRimegepant Sulfate28$50,766
Emgality PenGalcanezumab-Gnlm47$36,625
Aimovig AutoinjectorErenumab-Aooe40$33,638
Dimethyl Fumarate25$17,399
Lacosamide45$11,756
Levetiracetam324$9,748
Oxcarbazepine73$6,990
Carbidopa-LevodopaCarbidopa/Levodopa185$5,076
Gabapentin266$4,588
Lamotrigine101$3,275
Divalproex Sodium88$3,210
Baclofen162$3,199
Carbamazepine ErCarbamazepine24$2,947
Donepezil Hcl236$2,774

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt, Dilantin$639$53,36240 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 671 adult health providers in Massachusetts.

Other adult health in Abington

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →